Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Feb 12, 2025

SELL
$14.83 - $20.18 $103,810 - $141,260
-7,000 Closed
0 $0
Q4 2023

Feb 12, 2025

BUY
$13.43 - $19.63 $94,010 - $137,410
7,000 New
7,000 $134 Million

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $864M
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Bit Capital Gmb H Portfolio

Follow Bit Capital Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bit Capital Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Bit Capital Gmb H with notifications on news.